focus -WSS

focus

author：comprehensive 2025-10-01 10:51:51 - browse：728

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Senators push IRS to launch nonprofit hospital probe

hotspot

WSS

6 phony surgeries that take placebo to the extreme

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Alabama hospital puts IVF treatments on hold

In utero gene editing: an explainer

Maui wildfire now ranks as the fifth

entertainment

focus

Wikipedia

Supreme Court strikes down use of affirmative action

Why palliative psychiatry is worth discussing

Dobbs anniversary: the lost opportunity of abortion as health care

Surge in Apellis stock fueled by confidence in safety of its eye drug

Moonlake's readout produced a cash windfall. Risks remain

Dario to buy mental health app maker Twill in cash and stock deal

At least 13 dead in Texas as scorching temps continue

Antivenom research: Lessons from HIV applied in search for universal antidote

Virginia high school admissions case could be legal follow

Timeline: How the deadly wildfires took over Maui day by day

entertainment

Obesity drugs seen as possible treatment for liver disease MASH

Megan Rapinoe shares emotional post following US Women's World Cup exit

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

A new nitrogen execution bill also undermines medical licensing

Hospitals are dialing back on venture capital investing

Readout LOUD podcast: Humira legacy, AbbVie CEO's retirement

hotspot

hotspot

hotspot

knowledge